Literature DB >> 22627074

Bradyarrhythmias and conduction blocks.

Julia Vogler1, Günter Breithardt, Lars Eckardt.   

Abstract

Bradyarrhythmias are a common clinical finding and comprise a number of rhythm disorders including sinus node dysfunction and atrioventricular conduction disturbances. Clinical presentation varies from asymptomatic electrocardiogram findings (eg, during a routine examination) to a wide range of symptoms such as heart failure symptoms, near syncope or syncope, central nervous symptoms, or nonspecific and chronic symptoms such as dizziness or fatigue. Conditions resulting in bradyarrhythmic disorders are divided into intrinsic and extrinsic conditions causing damage to the conduction system. Furthermore bradyarrhythmias can be a normal physiologic reaction under certain circumstances. A proper diagnosis including a symptom-rhythm correlation is extremely important and is generally established by noninvasive diagnostic studies (12-lead electrocardiogram, Holter electrocardiogram, exercise testing, event recorder, implantable loop recorder). Invasive electrophysiologic testing is rarely required. If reversible extrinsic causes of bradyarrhythmias such as drugs (most often beta-blockers, glycosides and/or calcium channel blockers) or underlying treatable diseases are ruled out, cardiac pacing is usually the therapy of choice in symptomatic bradyarrhythmias. In this article of the current series on arrhythmias we will review the pathophysiology, diagnosis and treatment options of bradyarrhythmias, especially sinus node dysfunction and atrioventricular conduction blocks.
Copyright © 2012 Sociedad Española de Cardiología. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22627074     DOI: 10.1016/j.recesp.2012.01.025

Source DB:  PubMed          Journal:  Rev Esp Cardiol (Engl Ed)        ISSN: 1885-5857


  7 in total

1.  Imaging left-ventricular mechanical activation in heart failure patients using cine DENSE MRI: Validation and implications for cardiac resynchronization therapy.

Authors:  Daniel A Auger; Kenneth C Bilchick; Jorge A Gonzalez; Sophia X Cui; Jeffrey W Holmes; Christopher M Kramer; Michael Salerno; Frederick H Epstein
Journal:  J Magn Reson Imaging       Date:  2017-01-09       Impact factor: 4.813

Review 2.  Cardiomyopathy induced by artificial cardiac pacing: myth or reality sustained by evidence?

Authors:  Andrés Di Leoni Ferrari; Anibal Pires Borges; Luciano Cabral Albuquerque; Carolina Pelzer Sussenbach; Priscila Raupp da Rosa; Ricardo Medeiros Piantá; Mario Wiehe; Marco Antônio Goldani
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Jul-Sep

3.  Atrioventricular block in coronary artery bypass surgery: perioperative predictors and impact on mortality.

Authors:  Ricardo Medeiros Piantá; Andres Di Leoni Ferrari; Aline Almeida Heck; Débora Klein Ferreira; Jacqueline da Costa Escobar Piccoli; Luciano Cabral Albuquerque; João Carlos Vieira da Costa Guaragna; João Batista Petracco
Journal:  Rev Bras Cir Cardiovasc       Date:  2015 Mar-Apr

4.  Liver-specific NG37 overexpression leads to diet-dependent fatty liver disease accompanied by cardiac dysfunction.

Authors:  Xin Zhou; MengMeng Xu; Liyang Wang; Yulian Mu; Rui Feng; Zhilong Dong; Yuexin Pan; Xunzhang Chen; Yongfeng Liu; Shangen Zheng; Donald D Anthony; Jianjie Ma; Williams B Isaacs; Xuehong Xu
Journal:  Genes Nutr       Date:  2016-05-21       Impact factor: 5.523

5.  Matrix metalloproteinase 1 1 G/2 G gene polymorphism is associated with acquired atrioventricular block via linking a higher serum protein level.

Authors:  Jan-Yow Chen; Kuan-Cheng Chang; Ying-Ming Liou
Journal:  Sci Rep       Date:  2020-06-18       Impact factor: 4.379

Review 6.  Evaluation and Management of Asymptomatic Bradyarrhythmias.

Authors:  Göksel Çinier; Sohaib Haseeb; Giorgos Bazoukis; Cynthia Yeung; E Elvin Gül
Journal:  Curr Cardiol Rev       Date:  2021

Review 7.  Vagomimetic effects of fingolimod: physiology and clinical implications.

Authors:  Emilio Vanoli; Francesco Pentimalli; Gianluca Botto
Journal:  CNS Neurosci Ther       Date:  2014-06       Impact factor: 5.243

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.